Total Payments
$1,421
2024 Payments
$43.59
Companies
19
Transactions
46
Medicare Patients
3,434
Medicare Billing
$385,791
Payment Breakdown by Category
Food & Beverage$932.43 (65.6%)
Other$299.10 (21.1%)
Education$189.13 (13.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $932.43 | 38 | 65.6% |
| Long term medical supply or device loan | $299.10 | 3 | 21.1% |
| Education | $189.13 | 5 | 13.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $357.98 | 13 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $325.60 | 6 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $161.37 | 3 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $99.95 | 1 | $0 (2022) |
| Eisai Inc. | $63.81 | 3 | $0 (2024) |
| GENZYME CORPORATION | $60.90 | 2 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $58.16 | 3 | $0 (2023) |
| Celgene Corporation | $54.04 | 2 | $0 (2022) |
| ABBVIE INC. | $35.12 | 2 | $0 (2024) |
| Astellas Pharma US Inc | $29.32 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43.59 | 3 | Eisai Inc. ($26.70) |
| 2023 | $134.70 | 7 | Seagen Inc. ($27.88) |
| 2022 | $638.17 | 15 | E.R. Squibb & Sons, L.L.C. ($212.69) |
| 2021 | $604.20 | 21 | Novartis Pharmaceuticals Corporation ($325.60) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/15/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: ONCOLOGY | ||||||
| 03/21/2024 | Eisai Inc. | Lenvima (Drug) | Education | Cash or cash equivalent | $13.35 | General |
| Category: Oncology | ||||||
| 03/20/2024 | Eisai Inc. | Lenvima (Drug) | Education | Cash or cash equivalent | $13.35 | General |
| Category: Oncology | ||||||
| 10/10/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: Oncology | ||||||
| 03/07/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: ONCOLOGY | ||||||
| 02/17/2023 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Oncology | ||||||
| 02/01/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $25.42 | General |
| Category: Oncology | ||||||
| 01/27/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: ONCOLOGY | ||||||
| 01/18/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $12.50 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 01/05/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Oncology | ||||||
| 12/07/2022 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 12/07/2022 | GENZYME CORPORATION | SARCLISA (Biological), ELITEK | Food and Beverage | In-kind items and services | $38.12 | General |
| Category: Oncology | ||||||
| 11/04/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $4.94 | General |
| Category: Oncology | ||||||
| 11/02/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $32.78 | General |
| Category: Hematology | ||||||
| 10/28/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2022 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Education | In-kind items and services | $50.56 | General |
| Category: Oncology | ||||||
| 10/11/2022 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: BioOncology | ||||||
| 09/07/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: Hematology | ||||||
| 07/27/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $6.15 | General |
| 07/05/2022 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $37.11 | General |
| Category: Oncology | ||||||
| 06/15/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.26 | General |
| Category: Hematology | ||||||
| 05/25/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.88 | General |
| 05/18/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $116.49 | General |
| Category: Oncology | ||||||
| 05/11/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.67 | General |
| Category: Oncology | ||||||
| 05/04/2022 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 416 | 10,506 | $110,765 | $34,303 |
| 2022 | 23 | 764 | 28,482 | $354,514 | $94,055 |
| 2021 | 32 | 1,304 | 29,963 | $454,889 | $154,543 |
| 2020 | 20 | 950 | 29,827 | $299,285 | $102,890 |
Total Patients
3,434
Total Services
98,778
Medicare Billing
$385,791
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 2 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 27 | 49 | $2,940 | $1,177 | 40.0% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 20 | 49 | $4,900 | $1,079 | 22.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 16 | 51 | $3,825 | $1,033 | 27.0% |
| 96374 | Injection of drug or substance into vein | Office | 2022 | 22 | 37 | $4,403 | $970.02 | 22.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 13 | 19 | $2,525 | $906.34 | 35.9% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2022 | 12 | 4,350 | $17,400 | $605.85 | 3.5% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2022 | 40 | 68 | $2,448 | $566.39 | 23.1% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2022 | 13 | 420 | $20,160 | $298.51 | 1.5% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 11 | 64 | $128.00 | $79.02 | 61.7% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2022 | 38 | 63 | $126.00 | $63.86 | 50.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 17 | 588 | $1,176 | $54.10 | 4.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 14 | 44 | $44.00 | $29.04 | 66.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 233 | 568 | $104,776 | $44,601 | 42.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 187 | 383 | $47,602 | $21,345 | 44.8% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 60 | 207 | $62,595 | $21,027 | 33.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2021 | 21 | 17,850 | $60,690 | $13,401 | 22.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 13 | 79 | $37,406 | $10,664 | 28.5% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 48 | 287 | $19,375 | $6,150 | 31.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 63 | 89 | $7,180 | $5,432 | 75.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 48 | 104 | $15,792 | $5,085 | 32.2% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 15 | 64 | $9,712 | $3,551 | 36.6% |
| 96361 | Hydration infusion into a vein | Office | 2021 | 64 | 352 | $10,967 | $3,192 | 29.1% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2021 | 23 | 62 | $9,223 | $3,053 | 33.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 26 | 26 | $7,430 | $2,846 | 38.3% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 29 | 131 | $9,032 | $2,812 | 31.1% |
About Marles Geist, RN, ARNP
Marles Geist, RN, ARNP is a Adult Health healthcare provider based in Chehalis, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/07/2009. The National Provider Identifier (NPI) number assigned to this provider is 1073759486.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Marles Geist, RN, ARNP has received a total of $1,421 in payments from pharmaceutical and medical device companies, with $43.59 received in 2024. These payments were reported across 46 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($932.43).
As a Medicare-enrolled provider, Geist has provided services to 3,434 Medicare beneficiaries, totaling 98,778 services with total Medicare billing of $385,791. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Adult Health
- Location Chehalis, WA
- Active Since 01/07/2009
- Last Updated 05/12/2014
- Taxonomy Code 363LA2200X
- Entity Type Individual
- NPI Number 1073759486
Products in Payments
- KISQALI (Drug) $307.38
- OPDIVO (Biological) $281.39
- LYNPARZA (Drug) $125.00
- JEVTANA (Drug) $99.95
- Lenvima (Drug) $63.81
- IMBRUVICA (Drug) $58.16
- REBLOZYL (Biological) $54.04
- OPDUALAG (Drug) $50.56
- SARCLISA (Biological) $38.12
- TUKYSA (Drug) $27.88
- Vonjo (Drug) $25.08
- Enhertu (Drug) $24.67
- LIBTAYO (Biological) $22.78
- VENCLEXTA (Biological) $22.62
- MONJUVI (Drug) $18.43
- VENCLEXTA (Drug) $18.23
- VERZENIO (Drug) $17.23
- EPKINLY (Drug) $16.89
- Xtandi (Drug) $16.68
- GAVRETO (Drug) $14.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.